Tabrecta (capmatinib tablets - Novartis) — Cigna
Non-Small Cell Lung Cancer
Initial criteria
- Patient age ≥ 18 years
- Patient has advanced or metastatic disease
- Patient meets ONE of the following: (i) Patient has mesenchymal epithelial transition (MET) exon 14 skipping mutations as detected by an approved test OR (ii) Patient has high-level MET amplification as detected by an approved test
Approval duration
1 year